{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:17:43Z","timestamp":1790183863986,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.intimp.2019.105829","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T16:21:32Z","timestamp":1566231692000},"page":"105829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection"],"prefix":"10.1016","volume":"75","author":[{"given":"Zohre","family":"Sadeghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Fasihi-Ramandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Bouzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2019.105829_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3201\/eid0302.970219","article-title":"Brucellosis: an overview","volume":"3","author":"Corbel","year":"1997","journal-title":"Emerg. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2019.105829_bb0010","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.ajpath.2015.03.003","article-title":"Pathogenesis and immunobiology of brucellosis: review of Brucella\u2013host interactions","volume":"185","author":"de Figueiredo","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.20506\/rst.32.1.2187","article-title":"Epidemiology of brucellosis in domestic animals caused by Brucella melitensis, Brucella suis and Brucella abortus","volume":"32","author":"Aparicio","year":"2013","journal-title":"Rev sci tech Off int Epiz"},{"issue":"12","key":"10.1016\/j.intimp.2019.105829_bb0020","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/IAI.73.12.8079-8088.2005","article-title":"Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection","volume":"73","author":"Cassataro","year":"2005","journal-title":"Infect. Immun."},{"issue":"31","key":"10.1016\/j.intimp.2019.105829_bb0025","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.vaccine.2015.05.057","article-title":"Immune response triggered by Brucella abortus following infection or vaccination","volume":"33","author":"Dorneles","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2019.105829_bb0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-animal-021815-111326","article-title":"Brucella spp. virulence factors and immunity","volume":"4","author":"Byndloss","year":"2016","journal-title":"Annual review of animal biosciences"},{"issue":"1\u20134","key":"10.1016\/j.intimp.2019.105829_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0378-1135(02)00223-7","article-title":"The innate immune response against Brucella in humans","volume":"90","author":"Dornand","year":"2002","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.intimp.2019.105829_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/743509","article-title":"A history of the development of Brucella vaccines","volume":"2013","author":"Avila-Calder\u00f3n","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13567-015-0199-7","article-title":"Recent advances in Brucella abortus vaccines","volume":"46","author":"Dorneles","year":"2015","journal-title":"Vet. Res."},{"issue":"10","key":"10.1016\/j.intimp.2019.105829_bb0050","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1128\/IAI.71.10.5750-5755.2003","article-title":"Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used","volume":"71","author":"Velikovsky","year":"2003","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.intimp.2019.105829_bb0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/apm.12400","article-title":"Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections","volume":"123","author":"Abkar","year":"2015","journal-title":"Apmis"},{"key":"10.1016\/j.intimp.2019.105829_bb0060","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.2147\/IJN.S149774","article-title":"Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection","volume":"12","author":"Abkar","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1128\/IAI.01151-08","article-title":"Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection","volume":"77","author":"Pasquevich","year":"2009","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.intimp.2019.105829_bb0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.molimm.2015.01.009","article-title":"Vaccination with recombinant L7\/L12-truncated Omp31 protein induces protection against Brucella infection in BALB\/c mice","volume":"65","author":"Golshani","year":"2015","journal-title":"Mol. Immunol."},{"issue":"4\u20135","key":"10.1016\/j.intimp.2019.105829_bb0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijmm.2017.03.004","article-title":"Protein\/protein, DNA\/DNA and DNA\/protein based vaccination strategies using truncated Omp2b against Brucella infection in BALB\/c mice","volume":"307","author":"Golshani","year":"2017","journal-title":"International journal of medical microbiology"},{"issue":"49","key":"10.1016\/j.intimp.2019.105829_bb0080","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1016\/j.vaccine.2014.09.013","article-title":"Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection","volume":"32","author":"Ghasemi","year":"2014","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.intimp.2019.105829_bb0085","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2217\/nnm.14.187","article-title":"Recent advances in peptide-based subunit nanovaccines","volume":"9","author":"Skwarczynski","year":"2014","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.intimp.2019.105829_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4161\/hv.1.3.1851","article-title":"Towards an epitope-based human vaccine for influenza","volume":"1","author":"Ben-Yedidia","year":"2005","journal-title":"Human Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2019.105829_bb0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0952-7915(03)00083-9","article-title":"Epitope-based vaccines: an update on epitope identification, vaccine design and delivery","volume":"15","author":"Sette","year":"2003","journal-title":"Curr. Opin. Immunol."},{"issue":"36","key":"10.1016\/j.intimp.2019.105829_bb0100","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1016\/j.vaccine.2009.05.009","article-title":"Therapeutic efficacy of a multi-epitope vaccine against helicobacter pylori infection in BALB\/c mice model","volume":"27","author":"Zhou","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2019.105829_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2016.04.016","article-title":"A novel recombinant multi-epitope protein against Brucella melitensis infection","volume":"175","author":"Yin","year":"2016","journal-title":"Immunol. Lett."},{"issue":"7","key":"10.1016\/j.intimp.2019.105829_bb0110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly (I: C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2019.105829_bb0115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2015.966085","article-title":"Vaccine adjuvant uses of poly-IC and derivatives","volume":"14","author":"Martins","year":"2015","journal-title":"Expert review of vaccines"},{"issue":"10","key":"10.1016\/j.intimp.2019.105829_bb0120","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.addr.2013.05.013","article-title":"Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant","volume":"65","author":"Hafner","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2019.105829_bb0125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/CVI.00066-11","article-title":"Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice","volume":"18","author":"Xu","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.intimp.2019.105829_bb0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fimmu.2017.00125","article-title":"Immunogenicity of a multi-epitope Dna vaccine encoding epitopes from cu\u2013Zn superoxide dismutase and open reading frames of Brucella abortus in mice","volume":"8","author":"Escalona","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2019.105829_bb0135","series-title":"Seminars in Immunology","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","year":"2018"},{"issue":"2","key":"10.1016\/j.intimp.2019.105829_bb0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel","year":"2011","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.intimp.2019.105829_bb0145","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2019.105829_bb0150","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1473-3099(11)70099-8","article-title":"Targeting of toll-like receptors: a decade of progress in combating infectious diseases","volume":"11","author":"Hedayat","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.20506\/rst.32.1.2190","article-title":"Immunity to brucellosis","volume":"32","author":"Skendros","year":"2013","journal-title":"Rev. Sci. Tech."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1297-9716-43-29","article-title":"What have we learned from brucellosis in the mouse model?","volume":"43","author":"Grill\u00f3","year":"2012","journal-title":"Vet. Res."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.13041\/jpvm.2014.38.1.26","article-title":"Host immune responses during Brucella infection: a brief review","volume":"38","author":"Sung","year":"2014","journal-title":"Journal of Preventive Veterinary Medicine"},{"key":"10.1016\/j.intimp.2019.105829_bb0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.molimm.2018.10.002","article-title":"Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7\/L12+ rTOmp31+ rSOmp2b) in two different adjuvant formulations in BALB\/c mice","volume":"103","author":"Golshani","year":"2018","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2019.105829_bb0175","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1128\/IAI.69.10.6541-6544.2001","article-title":"Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection","volume":"69","author":"Pasquali","year":"2001","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2014.06.017","article-title":"Identification of a new immunogenic candidate conferring protection against Brucella melitensis infection in mice","volume":"62","author":"Ghasemi","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2019.105829_bb0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CMR.16.1.65-78.2003","article-title":"Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans","volume":"16","author":"Ko","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2019.105829_bb0190","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1574-6976.2010.00211.x","article-title":"Towards a Brucella vaccine for humans","volume":"34","author":"Perkins","year":"2010","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.intimp.2019.105829_bb0195","article-title":"Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis","volume":"1302561","author":"Vitry","year":"2014","journal-title":"J. Immunol."},{"issue":"07","key":"10.1016\/j.intimp.2019.105829_bb0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3855\/jidc.6625","article-title":"Host response to Brucella infection: review and future perspective","volume":"9","author":"Elfaki","year":"2015","journal-title":"The Journal of Infection in Developing Countries"},{"issue":"45","key":"10.1016\/j.intimp.2019.105829_bb0205","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1016\/j.vaccine.2010.08.098","article-title":"Poly (I: C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to plasmodium falciparum circumsporozoite protein (CSP) and \u03b1DEC-CSP in non human primates","volume":"28","author":"Tewari","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2019.105829_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12538","article-title":"Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly (I: C) in BALB\/c mice","volume":"40","author":"Mehrizi","year":"2018","journal-title":"Parasite Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2019.105829_bb0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.antiviral.2012.11.009","article-title":"Poly (I: C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs","volume":"97","author":"Cao","year":"2013","journal-title":"Antivir. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:18:07Z","timestamp":1749539887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919314754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":43,"alternative-id":["S1567576919314754"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105829","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105829"}}